



# Financial Tear Sheet


## Corporate Profile

G1 Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for the treatment of cancer. G1's two clinical assets, trilaciclib and G1T38, are CDK4/6 inhibitors, a validated and promising class of targets for anti-cancer therapeutics. Trilaciclib and G1T38 have broad therapeutic potential in many forms of cancer and may serve as the backbone of multiple combination regimens. In addition, G1 is advancing G1T48, a potential first/best-in-class oral selective estrogen receptor degrader, or SERD, which is targeted for the treatment of ER+ breast cancer. G1 owns or holds an exclusive license for worldwide commercial rights to each of its product candidates.

## Stock Performance

### GTHX (Common Stock)

Exchange	NASDAQ GS (US Dollar)
Price	<b>\$19.69</b>
Change (%)	▼ 0.41 (2.04%)
Volume	41,512
52 Week Low	\$12.04
Market Cap	\$558,118,642
Rolling EPS	-2.15
PE Ratio	0
Shares Outstanding	28,345,284



Data as of 02/16/18 4:00 p.m. ET

## Recent Headlines

02/14/18

G1 Therapeutics to Report Fourth Quarter and Full-Year 2017 Financial Results on February 21, 2018

---

01/02/18

G1 Therapeutics to Present at 36th Annual J.P. Morgan Healthcare Conference

---

12/18/17

G1 Therapeutics Added to Nasdaq Biotechnology Index

---

## Recent Events

<b>Date</b>	<b>Title</b>
02/21/18 4:30 p.m. ET	<b>Q1 2018 G1 Therapeutics, Inc. Earnings Conference Call</b>

---

## SEC Filings

<b>Filing Date</b>	<b>Form</b>	<b>Description</b>
02/16/18	4	Statement of changes in beneficial ownership of securities
02/16/18	4	Statement of changes in beneficial ownership of securities
02/13/18	SC 13D	Filing by person(s) reporting owned shares of common stock in a public company >5%
02/13/18	SC 13G	A statement of beneficial ownership of common stock by certain persons

---

Data provided by Nasdaq. Minimum 15 minutes delayed. View [Attributions and Sources](#)